

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	. CONFIRMATION NO
09/581,587	. 09/11/2000	Klaus Abraham-Fuchs	P00.1120 1296	
75	90 04/19/2005		EXAM	INER
Schiff Hardin & Waite 6600 Sears Tower			PATEL, NIHIR B	
Chicago, IL 60606			ART UNIT	PAPER NUMBER
-			3743	
			DATE MAILED, 04/10/2004	_

DATE MAILED: 04/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/581,587	ABRAHAM-FUCHS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Nihir Patel	3743			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period to - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
3) Since this application is in condition for allowar	action is non-final. nce except for formal matters, pro				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ☐ Claim(s) is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>19-36</u> is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplished any accomplished may not request that any objection to the Replacement drawing sheet(s) including the correct accordance to the second sec	epted or b) objected to by the l drawing(s) be held in abeyance. See ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 06.15.2000	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal F 6)  Other:				

Application/Control Number: 09/581,587

Art Unit: 3743

#### DETAILED ACTION

#### **Priority**

Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). The certified copy has been filed in parent Application No 09/581587 filed on September 11<sup>th</sup>, 2000.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 19, 25, 28, 29 and 36 are rejected under 35 U.S.C. 102(e) as being anticipated by Coutre et al (US 5,643,212).

Referring to claim 19, Coutre discloses an infusion pump management system for suggesting an adapted course of therapy that comprises a sensor 608 (see figure 37 and column 14 lines 35-37) for emitting real-times values representing a physiological parameter of a patient;

a control unit 610 (see figure 37 and column 14 lines 20-23) supplied with the real-times values (see column 14 lines 44-46); a fluid administration device selected from the group consisting f infusion devices and perfusion devices 402 (see figure 30 and column 9 lines 16-20), in communication with the control unit 610, the fluid administration device containing a solution to be administered (see column 9 lines 16-20); the control unit 610 controlling the fluid administration device to dispense the solution dependent on the real-time values (see column 14 lines 45-60); and the control unit 610 comprising an expert system which processes the real-times values as the real times values are received from the sensor, to obtain a processes result, and the control unit continually updating of the fluid administration device dependent on the processed result (see column 14 lines 45-60 and column 15 lines 1-15).

Referring to **claim 25**, Coutre discloses an apparatus wherein the control unit **610**, based on the processed results, automatically controls the fluid administration device to change dispensing of the solution to adjust for a deficient supply, a balanced supply and an excess supply of the solution (see column 14 lines 45-60).

Referring to claim 28, Coutre discloses an apparatus that further comprises an alarm connected to the control unit, the alarm being triggered by the control unit dependent on at leat one of the real-time values (see column 12 lines 45-60).

Referring to claim 29, Coutre discloses an apparatus wherein the sensor 608 is a sensor from the group consisting of glucose sensors (see column 14 lines 35-40) and potassium sensors, and wherein the control unit 610 controls the fluid administration device to administer a fluid for influencing a metabolism selected from the group consisting of glucose metabolism and potassium metabolism.

Referring to claim 36, Coutre discloses an apparatus wherein the sensor 608 is a sensor selected from the group consisting of a sensor for measuring temperature of the patient (see column 14 lines 35-44).

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Coutre et al. (US 5,643,212).

Referring to claim 20, the applicant claims a fluid administration device that comprises plurality o different solutions to be administered in respectively different dispensed amounts, and wherein the control unit controls administration of the different solutions in the different dispensed amounts dependent on the processing result. Coutre discloses plurality of solutions that are to be infused on additional lines (see column 9 lines 25-40). Therefore it is obvious to one in the ordinary skill of the art that the plurality of different solutions as taught by Coutre be administered in respectively different dispensed amount in order to provide the correct amount of the required solution to the patient.

Claims 21 through 24 and 32 through 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coutre et al. (US 5,643,212) in view of Uber, III et al. (US 5,840,026).

Referring to claims 21 through 24 and 32 through 35, Coutre discloses the applicant's invention as claimed with the exception of providing a mixing device connected to all of the

different solutions wherein the mixing device has a single outlet at which all of the different solutions are dispensed in the dispensed amount, controlled by either manually or control unit to a patient. Uber discloses a patient specific dosing contrast delivery systems and methods that does provide a mixing device 71 (see figure 3a) connected to all of the different solutions wherein the mixing device has a single outlet at which all of the different solutions are dispensed in the dispensed amount, controlled by either manually or control unit to a patient. Therefore it would have been obvious to modify Coutre's invention by providing a mixing device connected to all of the different solutions wherein the mixing device has a single outlet at which all of the different solutions are dispensed in the dispensed amount, controlled by either manually or control unit to a patient as taught by Uber in order to mix and deliver the correct amount of solution to the patient.

Claims 26 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coutre et al. (US 5,643,212) in view of Pfeiffer et al. (US 5,902,253).

Referring to claims 26, Coutre discloses the applicant's invention as claimed with the exception of providing a source of calibrating solution and rinsing and calibrating means connected to the sensor for rinsing the sensor and for calibrating the sensor with the calibrating solution. Pfeiffer discloses an apparatus for analyzing body fluids that does provide a source of calibrating solution and rinsing and calibrating means connected to the sensor for rinsing the sensor and for calibrating the sensor with the calibrating solution. Therefore it would have been obvious to modify Coutre's invention by providing a source of calibrating solution and rinsing and calibrating means connected to the sensor for rinsing the sensor and for calibrating the sensor with the calibrating solution as taught by Pfeiffer in order to obtain accurate results.

Referring to claim 27, Coutre discloses the applicant's invention as claimed with the exception of providing rinsing and calibrating means that is connected to and controlled by the control unit. Pfeiffer discloses an apparatus for analyzing body fluids that does provide rinsing and calibrating means that is connected to and controlled by the control unit. Therefore it would have been obvious to modify Coutre's invention by providing rinsing and calibrating means that is connected to and controlled by the control unit as taught by Pfeiffer in order to have the sensor in operating conditions at all times.

Claim 30 is rejected under 35 U.S.C. 103(a) as being unpatentable over Coutre et al. (US 5,643,212) in view of Thornton (US 5,263,491).

Referring to claim 30, Coutre discloses the applicant's invention as claimed with the exception of providing a sensor for sensing a parameter related to caloric metabolism. Thornton discloses an ambulatory metabolic monitor that does provide a sensor for sensing a parameter related to caloric metabolism. Therefore it would have been obvious to modify Coutre's invention by providing a sensor for sensing a parameter related to caloric metabolism as taught by Thornton in order to determine the quantity of solution to be given to the patient.

Claim 31 is rejected under 35 U.S.C. 103(a) as being unpatentable over Coutre et al. (US 5,643,212) in view of Chen et al. (US 5,670,057).

Referring to claim 31, Coutre discloses the applicant's invention as claimed with the exception of providing a sensor selected from the group consisting of fluid sensors and electrolyte sensors, and wherein the control unit controls the fluid administration device to administer a fluid for influencing a metabolism selected from the group consisting of fluid metabolism and electrolyte metabolism. Chen discloses an apparatus and method for

Application/Control Number: 09/581,587

Art Unit: 3743

Page 7

automatically performing peritoneal equilibration tests that does provide a sensor selected from

the group consisting of fluid sensors and electrolyte sensors, and wherein the control unit

controls the fluid administration device to administer a fluid for influencing a metabolism

selected from the group consisting of fluid metabolism and electrolyte metabolism. Therefore it

would have been obvious to modify Coutre's invention by providing a sensor selected from the

group consisting of fluid sensors and electrolyte sensors, and wherein the control unit controls

the fluid administration device to administer a fluid for influencing a metabolism selected from

the group consisting of fluid metabolism and electrolyte metabolism as taught by Chen in order

to obtain accurate information.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's

disclosure.

Any inquiry concerning this communication or earlier communication from the examiner

should be directed to Nihir Patel whose telephone number is (571) 272-4803. The examiner can

normally be reached on Monday-Friday from 7:30 am to 4:30 pm. If attempts to reach the

examiner by telephone are unsuccessful the examiner supervisor Henry Bennett can be reached

at (571) 272 4791.

NP

April 14<sup>th</sup>, 2005

Heil prenner

Sixpervisor Patent Examiner

Solun 2200